Steroid Hormone Receptors

Why steroid hormone receptors matter

• They convert a hormone into a change in gene expression. Surface receptors flip switches on proteins that already exist; steroid receptors reach into the genome and change the cell's protein inventory. That is why a single pulse of cortisol can reprogram metabolism for hours, mobilizing glucose, dampening the immune system, and reshaping the transcriptome of nearly every tissue at once.
• They are the most drugged transcription factors in medicine. Glucocorticoids (prednisone, dexamethasone), the contraceptive pill (synthetic estrogens and progestins), tamoxifen and aromatase inhibitors for breast cancer, anti-androgens like enzalutamide for prostate cancer, and mineralocorticoid blockers like spironolactone all act on steroid receptors. Nuclear receptors as a class are targeted by an estimated 13% of approved drugs.
• They read the endocrine axes. The hypothalamic–pituitary–adrenal axis ends at the glucocorticoid receptor; the hypothalamic–pituitary–gonadal axis ends at the estrogen and androgen receptors. These receptors are the molecular readout of every stress response, menstrual cycle, and pubertal transition.
• They explain tissue-selective hormone action. The same estradiol molecule builds bone, thickens the endometrium, and can drive breast tumors — because target tissues differ in receptor levels, coactivator/corepressor balance, and accessible chromatin. Selective estrogen receptor modulators (SERMs) like raloxifene exploit this, acting as agonists in bone but antagonists in breast.
• Their mutations cause disease. Loss-of-function mutations in the androgen receptor produce androgen insensitivity syndrome (a 46,XY individual develops a female phenotype); a CAG-repeat expansion in the same gene causes spinal and bulbar muscular atrophy (Kennedy disease); mineralocorticoid receptor gain-of-function drives early hypertension. Constitutively active androgen-receptor splice variants (AR-V7) drive castration-resistant prostate cancer.
• They keep pace on two clocks at once. The slow genomic arm rewrites the transcriptome over hours, while the fast nongenomic arm — membrane-associated receptors and GPER — lets estrogen dilate a coronary artery or a neuron fire differently within seconds. Coordinating both timescales lets one hormone handle both acute and chronic demands.

Common misconceptions

• "All hormone receptors sit on the cell surface." Only water-soluble hormones — peptides like insulin and glucagon, and catecholamines like adrenaline — need surface receptors. Lipophilic hormones (steroids, thyroid hormone, retinoic acid, vitamin D) pass through the membrane and use intracellular receptors that are themselves transcription factors.
• "Steroid receptors are always in the nucleus." Location varies by receptor. Glucocorticoid, mineralocorticoid, and androgen receptors are largely cytoplasmic when unliganded and translocate on hormone binding; estrogen and progesterone receptors are mostly nuclear already. The functional endpoint — a hormone-bound receptor on DNA — is the same.
• "Steroid signaling is always slow." The genomic arm is slow, but nongenomic effects unfold in seconds through membrane-associated receptors and second messengers. Estrogen-driven vasodilation via endothelial nitric oxide synthase and rapid neuronal effects of glucocorticoids are far too fast to involve transcription.
• "The receptor turns genes on." Steroid receptors both activate and repress. The glucocorticoid receptor tethers to NF-kB and AP-1 to shut down inflammatory genes (transrepression) as much as it activates metabolic genes. Whether a gene goes up or down depends on the coregulators the receptor recruits at that site.
• "Cortisol only fits the glucocorticoid receptor." Cortisol binds the mineralocorticoid receptor with comparable affinity. Kidney tubule cells protect that receptor by expressing 11-beta-hydroxysteroid dehydrogenase type 2, which oxidizes cortisol to inactive cortisone. Block that enzyme — as glycyrrhetinic acid in licorice does — and cortisol activates the mineralocorticoid receptor, causing salt retention and hypertension.
• "Testosterone is the active androgen everywhere." In many target tissues — prostate, skin, hair follicle — testosterone is reduced to the far more potent dihydrotestosterone (DHT) by 5-alpha-reductase before it binds the androgen receptor. Blocking that enzyme with finasteride is how benign prostatic hyperplasia and male-pattern baldness are treated.

How steroid hormone receptors work, step by step

A steroid hormone begins its life in an endocrine gland, synthesized from cholesterol by a chain of cytochrome-P450 and dehydrogenase enzymes. Once secreted it travels in blood largely bound to carrier proteins — cortisol on corticosteroid-binding globulin, sex steroids on sex-hormone-binding globulin — and only the small free fraction, typically a few percent, is biologically available. Because the molecule is lipophilic, that free hormone diffuses directly across the plasma membrane of a target cell rather than docking a surface receptor.

Inside the cell it meets its receptor. Classic steroid receptors are modular proteins with three functional regions: an N-terminal transactivation domain (AF-1), a central DNA-binding domain built from two zinc fingers, and a C-terminal ligand-binding domain that also carries a second activation function (AF-2). In the unliganded state a receptor such as the glucocorticoid receptor is held in the cytoplasm inside a chaperone complex — HSP90, HSP70, p23, and immunophilins like FKBP51 — that keeps the ligand-binding pocket in a high-affinity conformation but masks the receptor's nuclear-localization signal.

Hormone binding triggers the switch. When the steroid slots into the ligand-binding pocket, helix 12 of the ligand-binding domain snaps shut over the ligand like a lid, the chaperones dissociate, and the freshly exposed nuclear-localization signal ferries the receptor through nuclear pores into the nucleus. Two hormone-bound receptors then dimerize — glucocorticoid, androgen, and progesterone receptors form homodimers, and estrogen receptors likewise bind DNA mainly as homodimers (ERα/ERα or ERβ/ERβ), with ERα/ERβ heterodimers forming where both subtypes are co-expressed.

The dimer scans the genome for its hormone-response element, a short palindromic DNA sequence in the regulatory region of target genes. The glucocorticoid/androgen/progesterone/mineralocorticoid family reads inverted repeats of AGAACA, one receptor sitting on each half-site; the estrogen receptor reads AGGTCA half-sites. A short amino-acid loop called the P-box in the first zinc finger is what discriminates one half-site from another. Binding positions the receptor's AF-2 surface to recruit coregulators: coactivators of the p160/SRC family and the histone acetyltransferases CBP/p300 open chromatin and load the Mediator complex and RNA polymerase II, or, when the sequence and context call for it, corepressors (NCoR/SMRT) and histone deacetylases silence the gene. Cortisol's anti-inflammatory action works differently again — its receptor tethers as a monomer to the transcription factors NF-kB and AP-1 and represses their inflammatory target genes without ever touching DNA directly.

The result is a wave of new (or suppressed) transcription that plays out over 30 minutes to several hours, changing which proteins the cell makes. Running in parallel, a nongenomic arm operates in seconds: a fraction of receptor associated with the plasma membrane, or a dedicated membrane receptor like GPER, activates second messengers — calcium, cAMP, and the MAPK and PI3K/AKT kinase cascades — for rapid effects that need no new gene expression. Both arms are triggered by the same hormone, and physiological responses usually blend the two.

Steroid vs peptide hormone signaling

Feature	Steroid hormones (this concept)	Peptide / catecholamine hormones
Chemistry	Lipophilic, cholesterol-derived	Hydrophilic, protein or amine
Membrane crossing	Diffuses through bilayer	Cannot cross; binds cell surface
Receptor location	Cytoplasm / nucleus (intracellular)	Plasma membrane (surface)
Receptor is a	Ligand-activated transcription factor	GPCR or receptor tyrosine kinase
Second messenger	Usually none (genomic); Ca²⁺/cAMP (nongenomic)	cAMP, IP₃/DAG, Ca²⁺, kinases
Primary output	Changed gene transcription	Modified pre-existing proteins
Onset	30 min – hours (seconds nongenomic)	Milliseconds – seconds
Duration	Hours to days	Seconds to minutes
Blood transport	Carrier-protein bound (CBG, SHBG)	Mostly dissolved free in plasma
Example	Cortisol, estradiol, testosterone	Insulin, glucagon, adrenaline

Genomic vs nongenomic steroid action

Property	Genomic (classical)	Nongenomic (rapid)
Timescale	30 minutes to hours/days	Seconds to a few minutes
Site of action	Nucleus, on DNA	Plasma membrane / cytoplasm
Receptor	Intracellular nuclear receptor	Membrane-associated receptor, GPER
Mechanism	Binds HREs, alters transcription	Ca²⁺, cAMP, MAPK, PI3K/AKT
Needs new protein synthesis	Yes	No
Blocked by	Actinomycin D, cycloheximide	Kinase / channel inhibitors
Classic example	Cortisol inducing gluconeogenic enzymes	Estrogen activating eNOS → vasodilation

Cortisol, estrogen, and testosterone

Cortisol binds the glucocorticoid receptor (gene NR3C1), the anti-stress, anti-inflammatory master switch. Cytoplasmic at rest, it translocates on binding and both induces metabolic genes (gluconeogenesis, glycogen synthesis) and represses inflammatory ones by tethering to NF-kB. Synthetic mimics — dexamethasone, prednisone — are among the most prescribed drugs on Earth. Cortisol's cross-reactivity with the mineralocorticoid receptor is policed in the kidney by 11β-HSD2.

Estradiol binds two receptors, ERα (NR3A1) and ERβ (NR3A2), which are largely nuclear even without ligand. Beyond reproduction, estrogen maintains bone density, favorable lipid profiles, and vascular tone; its nongenomic arm relaxes blood vessels within minutes via GPER and eNOS. Because ~70% of breast cancers are ER-positive and estrogen-driven, the ER is the target of tamoxifen (a SERM), fulvestrant (a degrader), and aromatase inhibitors that cut off estrogen synthesis.

Testosterone binds the androgen receptor (gene AR on the X chromosome), largely cytoplasmic until liganded. In prostate, skin, and hair follicle it is first converted to the more potent dihydrotestosterone by 5α-reductase. Androgen-receptor signaling drives male sexual development, muscle mass, and — pathologically — prostate cancer, which is why androgen-deprivation therapy and AR antagonists like enzalutamide are mainstays of treatment. A CAG-repeat expansion in AR causes Kennedy disease; loss-of-function mutations cause androgen insensitivity syndrome.

Famous experiments and history

• Jensen's tritiated estradiol (1958–1968). Elwood Jensen synthesized radiolabeled estradiol of high specific activity and injected it into immature rats. Only estrogen target tissues — uterus, vagina — retained the hormone, and the retention was saturable and competable, the signature of a specific receptor. With Jack Gorski he formulated the two-step model: hormone binding, then nuclear translocation. Jensen received the 2004 Lasker Award.
• Yamamoto and Beato map the response element (late 1970s–1980s). Keith Yamamoto and Miguel Beato showed that the glucocorticoid receptor binds specific DNA sequences upstream of hormone-regulated genes and defined the glucocorticoid-response element as an inverted-repeat palindrome, establishing that the receptor acts directly on DNA to control transcription.
• Cloning the receptors (1985–1987). Ronald Evans's group cloned the human glucocorticoid receptor cDNA in 1985; Pierre Chambon's and Geoffrey Greene's groups cloned the estrogen receptor around the same time. The sequences revealed a shared modular design — a conserved zinc-finger DNA-binding domain flanked by variable transactivation and ligand-binding domains — and defined the nuclear receptor superfamily, now 48 human members including receptors for thyroid hormone, vitamin D, and retinoic acid.
• The zinc-finger structure (1988–1991). NMR and crystallography of the glucocorticoid and estrogen receptor DNA-binding domains revealed two zinc-coordinating modules and pinpointed the P-box residues that read the response-element half-site, explaining how closely related receptors recognize different DNA sequences.
• Helix-12 and the SERM mechanism (1997–1998). Crystal structures of the estrogen receptor ligand-binding domain bound to estradiol versus the antagonists raloxifene and 4-hydroxytamoxifen (Brzozowski et al., Nature 1997) showed that agonists let helix 12 close over the pocket to form the AF-2 coactivator groove, while antagonists push helix 12 into that groove and block it. This structural switch explains how one drug can be an ER agonist in bone and an antagonist in breast.